TY - JOUR T1 - Over-expression of CEP55 Predicts Favorable Prognosis in Colorectal Cancer Patients With Lymph Node Involvement JF - Anticancer Research JO - Anticancer Res SP - 543 LP - 547 DO - 10.21873/anticanres.14806 VL - 41 IS - 1 AU - REN-HUNG HUANG AU - WEN-KANG YANG AU - CHEUK MAN WU AU - CHUNG-MIN YEH AU - WEN-WEI SUNG Y1 - 2021/01/01 UR - http://ar.iiarjournals.org/content/41/1/543.abstract N2 - Background/Aim: To characterize the potential roles of CEP55 in colorectal cancer development and assess its eligibility as a prognostic diagnosis tool for colorectal cancer. Patients and Methods: Immunohistochemical (IHC) analysis of CEP55 immunoreactivity in 166 cancer specimens from colorectal cancer patients. Results: CEP55 was not found to statistically significantly affect different patient clinical parameters. Multivariate analysis illustrated that patients with N stage (1+2) colorectal cancer and high CEP55 expression had a significantly lower five-year survival rate than patients with N stage (1+2) colorectal cancer and low CEP55 expression. Conclusion: There is a correlation between CEP55 and advanced N-stage colorectal cancer. Thus, CEP55 may be a potential diagnostic biomarker for colorectal cancer patients. ER -